Novo Nordisk reports Q1 EPS DKK 5.68 vs. DKK 4.39 last year

Reports Q1 net sales DKK 65.35B vs. DKK 53.37B last year. Reports Q1 operating profit DKK 31.85B vs. DK 35.01B last year. Lars Fruergaard Jorgensen, president and CEO: “We are pleased with the sales growth in the first three months of 2024, driven by increased demand for our GLP-1-based diabetes and obesity treatments. More patients benefit from our innovative treatments, and the agreement to acquire the three Catalent manufacturing sites will enable us to serve significantly more people living with diabetes and obesity in the future. Within R&D, we are pleased with the positive results from the kidney outcomes trial with semaglutide and the label expansion for cardiovascular risk reduction for Wegovy in the US.”